U.S. markets closed

Alector, Inc. (ALEC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.23-0.14 (-0.66%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close21.37
Bid20.00 x 1000
Ask22.81 x 1000
Day's Range20.34 - 21.29
52 Week Range9.12 - 33.82
Avg. Volume669,325
Market Cap1.693B
Beta (5Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-2.57
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Alector to Present at Upcoming Virtual Healthcare Conferences

    Alector to Present at Upcoming Virtual Healthcare Conferences

    SOUTH SAN FRANCISCO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in fireside chats at the following upcoming virtual investor conferences: The Goldman Sachs 42nd Annual Global Healthcare Conference – Thursday, June 10, 2021, at 4:40 p.m. ETThe BofA Securities 2021 Napa Biopharm

  • CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia

    CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia

    Observational Study to Advance Genetic Understanding of FTD Being Conducted With Support From AlectorCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 02, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced a new observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia (FTD). The observational EFRONT

  • Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021

    Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021

    SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it will host a virtual key opinion leader event focused on frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) on Friday, June 11, 2021 at 10:30 a.m. ET. The agenda will include an overview of FTD-GRN and underlying pathophysiology, clinical endpoints, and the role of disease-relevant biomarkers that can inform the development of novel therapies for FTD-GRN. Alector management will also provide an overview of the ongoing development program for AL001 in FTD-GRN. The program will feature presentations from renowned neurology key opinion leaders, including: Henrik Zetterberg, M.D., Ph.D. Professor, Neurochemistry, University of Gothenburg, Sweden & University College London, UKHead of the Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, SwedenJonathan Rohrer, M.B., Ph.D. MRC Clinician Scientist, University College London, UK Honorary Consultant Neurologist, National Hospital for Neurology and Neurosurgery, Queen Square, London A live webcast of the event will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 30 days following the event. About AL001AL001 is a wholly owned, investigational human monoclonal antibody designed to modulate progranulin, a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including FTD, Alzheimer’s disease, and Parkinson’s disease. AL001 aims to increase the level of progranulin in humans by inhibiting a progranulin degradation mechanism. AL001 has received Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN from the U.S. Food and Drug Administration. About Frontotemporal Dementia (FTD)FTD is a rapidly progressing and severe form of dementia found most frequently in people less than 65 years old at the time of diagnosis. It affects 50,000 to 60,000 people in the United States and roughly 110,000 in the European Union. There are currently no FDA-approved treatments options for FTD. There are multiple heritable forms of FTD. In one form, FTD-GRN, people have a mutation in the progranulin gene. This population represents 5% to 10% of all people with FTD. Mutations in a single copy of progranulin gene (GRN) leads to a 50% or greater decrease in the level of progranulin and invariably leads to development of FTD. In another form, FTD-C9orf72, people with mutations in the C9orf72 gene can develop FTD. FTD-C9orf72 is associated with abnormal accumulation of the protein TDP-43, which is also a hallmark pathology found in FTD-GRN. About AlectorAlector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com. Contacts1ABDan Budwick973-271-6085dan@1abmedia.com or Investors:Alector, Inc.ir@alector.com